Clinical Trials · NCT02194595
Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Mount Sinai Hospital, Canada
- Enrollment
- 105
- Start date
- Sep 2014
- Locations
- 1 site, Canada
- Primary endpoint
- Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2)